CORRECTING and REPLACING -- TESARO Announces Expansion of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
CORRECTING and REPLACING -- TESARO Announces Expansion of Niraparib Clinical Program and Outlines Late-Stage Program Milestones for 2015

-- New trial of niraparib for the treatment of ovarian cancer to begin in Q1 2015 
-- HRD assay to be incorporated into Phase 3 NOVA trial of niraparib in ovarian cancer 
-- Initial Phase 3 data from NOVA is expected to become available in 2015 
-- U.S. FDA PDUFA action date for oral rolapitant is September 5, 2015

WALTHAM, Mass., Jan. 12, 2015 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by TESARO, Inc. (Nasdaq: TSRO ), please note that in the fourth line of the subhead, the U.S. FDA PDUFA action date for oral rolapitant should be September 5, 2015, not September 4, 2015, as originally stated. This same change should be noted in the first paragraph of the  Rolapitant section. There were no other changes to the release.

The corrected release follows:

TESARO, Inc. (Nasdaq: TSRO ), an oncology-focused biopharmaceutical company, today provided an update on its late-stage programs.

"With a potential near-term product launch and a robust, oncology-focused pipeline that is balanced across stages of development and level of risk, we believe that TESARO is uniquely positioned within the biopharmaceutical industry," said Lonnie Moulder, CEO of TESARO. "Since the Company was founded in 2010, we have in-licensed 10 product candidates, completed our first pivotal development program, submitted our first NDA, and we expect to report data from the Phase 3 NOVA trial of niraparib later this year. We are very pleased to be implementing such a comprehensive niraparib development program for women with ovarian cancer, including both the treatment and maintenance settings, and across multiple lines of therapy. 2015 will be a defining year for TESARO as the Company transitions to become an integrated development and commercial organization in support of our first potential product launch."

Rolapitant

Oral rolapitant, an NK-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting (CINV), is the subject of a New Drug Application (NDA) that is currently under review by the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Action (PDUFA) goal date of September 5, 2015. An intravenous (IV) formulation of rolapitant is being compared to oral rolapitant in an ongoing clinical trial designed to demonstrate bioequivalence.

TESARO anticipates completing the following milestones related to rolapitant in 2015:

  • Establish a full-scale oncology U.S. commercial organization to support the launch of rolapitant by the third quarter; and
  • Submit an NDA for IV rolapitant following regulatory approval of oral rolapitant.

Niraparib

Niraparib is a potent, oral PARP inhibitor that is currently being evaluated in two ongoing Phase 3 trials in patients with ovarian cancer (the NOVA trial) and for treatment of BRCA-positive breast cancer (the BRAVO trial).  

Enrollment of the originally intended 180 patients in the non-germline BRCA cohort of the NOVA trial was completed as planned in the fourth quarter of 2014. In order to incorporate a homologous recombination deficiency (HRD) assay into NOVA, the sample size of the non-germline BRCA cohort was increased by 130 patients. Enrollment was expanded in late 2014 and is expected to complete during the first quarter of 2015. The Company expects to report initial data from the NOVA study during 2015.

A new trial supporting registration of niraparib for the treatment of patients with ovarian cancer is planned to initiate during the first quarter of 2015. This single arm, open label study is targeted to enroll 225 patients who have received three or more prior lines of chemotherapy, and endpoints will include objective response rate (ORR) and duration of response for the entire population, as well as platinum sensitive, platinum resistant, germline BRCA and HRD patient subsets.

TESARO anticipates completing the following milestones related to niraparib in 2015:

  • Initiate a potential registration trial of niraparib for the treatment of patients with ovarian cancer who have previously been treated with three prior regimens of therapy during the first quarter;
  • Complete enrollment of the expanded non-gBRCA cohort within the NOVA trial during the first quarter;
  • Report initial data from NOVA during 2015; and
  • Initiate trials of niraparib in the small cell lung cancer (SCLC) and first-line ovarian cancer maintenance settings during the second half of 2015.

Year-End 2014 Cash Position

TESARO ended 2014 with approximately $257 million in cash and cash equivalents (unaudited), which should provide sufficient resources to enable continued execution on development of the Company's product pipeline and fund commercialization activities for rolapitant. TESARO expects an average cash burn in the low-$40 million range per quarter in the first half of 2015.

About TESARO

TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients by acquiring, developing and commercializing safer and more effective therapeutics. For more information, visit www.tesarobio.com .

To the extent that statements contained in this press release are not descriptions of historical facts regarding TESARO, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Examples of forward looking statements contained in this press release include, among others, statements regarding our expectations regarding the timing of both the selection of clinical candidates from the programs and the commencement of clinical testing, our development plans for any antibody therapeutic candidates individually and in combination with other products and product candidates, and our ability to form partnerships in the future in support of our overall oncology strategy. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our research and pre-clinical development programs, clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the initiation of future clinical trials, availability of data from ongoing clinical trials, expectations for regulatory approvals, patient accrual rates for clinical trials, certain expenditures and other matters that could affect the availability or commercial potential of our drug candidates. TESARO undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see TESARO's Annual Report on Form 10-K for the year ended December 31, 2013, and Quarterly Report on Form 10-Q for the quarter ended September 30, 2014.

TESARO Contact: Jennifer Davis Sr. Director, Corporate Development & Investor Relations +1.781.325.1116 or

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AES Clears FERC, Nearing Its December 2 Takeover Close

Updated Category News Views 119

One more regulatory gate just swung open for AES, and this deal is finally staring at the finish line instead of wandering through the usual approval swamp. The Federal Energy Regulatory Commission has issued its final order approving AES's acquisition by a consortium led by Global Infrastructure Partners, part of BlackRock, and EQT Infrastructure VI. The last major...

Continue Reading
Floating Solar Gets a Serious Test in Central New York

Updated Category News Views 114

A flooded quarry pit outside Cortlandville is getting a second career, and that is more interesting than another solar announcement draped across empty acreage. Third Pillar Power has started construction on Crown City Solar at Suit-Kote Corporation's active Polkville Crushed Stone Facility, pairing a working mine, asphalt plant, and storage terminal with what the...

Continue Reading
AMPERA Joins Berto to Power Future Energy Innovations

Updated Category News Views 172

The Power Play You Didn't See Coming AMPERA and Berto just made a move that could stir up some serious waves in the energy sector. They've inked a business combination deal set to push advanced energy technology to the forefront. With AMPERA's valuation clocking in at roughly $900 million, this partnership aims to bring cutting-edge power solutions from concept to market....

Continue Reading
Red Cat Stock Drama: Revenue Targets and Legal Waves

Updated Category News Views 110

Red Cat's Revenue Predictions Crash and Burn Sitting there on August 6, 2026, Red Cat Holdings had everyone believing they were on a fast track to hitting a hefty revenue target: $150–$180 million for FY2026. CEO Jeffrey Thompson didn't mince words, boasting confidence like a captain before a storm. Fast forward three months, and they're waving the white flag, tossing...

Continue Reading
Palm Beach Loan Company Tests Luxury Lending Demand

Updated Category News Views 103

Jewelry in a safe is dead capital until somebody lends against it. That plain fact sits behind Luxury Asset Capital's latest move: the launch of Palm Beach Loan Company, a South Florida brand aimed at wealthy owners of watches, diamonds, art, handbags, gold, collectibles, and other high-value possessions. The company is not asking clients to sell the stuff they spent...

Continue Reading
Finzly Welcomes Paul Finch to Drive BankOS Growth

Updated Category News Views 42

Finzly's Strategic Move to Boost Innovation Alright, folks, it seems Finzly means business. They just roped in Paul Finch, the brains who gave us Zelle during his stint as CEO over at Early Warning Services. This guy's been around the block with a couple of the biggest names in banking, and if his past headlines are any indicator, he's got the knack for shaking things up...

Continue Reading
Stand Out For Good Makes a Bold Michigan Avenue Bet

Updated Category News Views 183

A six-floor retail commitment lands with a thud Stand Out For Good is taking on roughly 51,079 square feet at 669 North Michigan Avenue, and nobody should mistake that for a casual expansion. Six levels on Chicago's Magnificent Mile is a proper declaration of intent, especially in a retail district that has endured plenty of empty-window handwringing and big-brand churn....

Continue Reading
Redseer's $5M Bet on Faster MENA Decision Intelligence

Updated Category News Views 7

Speed has become the expensive commodity in Middle Eastern commerce, and Redseer is putting roughly $5 million behind the idea that executives will pay to get it. Its newly launched Benchmarks MENA 2.0 platform combines proprietary market data with strategic advisory across nine MENA markets. That sounds like another corporate dashboard pitch until you consider the target...

Continue Reading
Skanska Adds $80M U.S. Tech Facility Contract to Orders

Updated Category News Views 29

An $80 million add-on is the sort of construction news that looks modest until you remember what it says about the customer relationship. Skanska has won an additional contract from an existing client for a U.S. tech facility, worth roughly SEK 760 million, and it will enter U.S. order bookings in the fourth quarter of 2026. No fireworks, no grand strategic...

Continue Reading
Madrigal Pharmaceuticals Faces Legal Scrutiny Over Data

Updated Category News Views 137

Legal Storm Brews for Madrigal Pharmaceuticals Watch out, here comes another storm for Madrigal Pharmaceuticals, folks. This ain't no small drizzle either; it's a full-on legal monsoon, and it's soaked straight through the walls of their executive suite. We're talking a whistleblower sending alarm bells ringing about data fudging and some dodgy boardroom maneuvers—as if...

Continue Reading

Top 5 Most Recently Viewed Articles

Recent Research Highlights the Distress of Captive Elephants

Updated Category News Views 249

Understanding the Distress of Elephants in Captivity A recent peer-reviewed study published in the journal Peer J has shed light on the overwhelming challenges that captive elephants continue to face within zoos despite ongoing efforts to improve conditions. This study stands as a significant testament to the struggles these majestic animals endure, raising essential...

Continue Reading
Exploring the Future of Paper-Based Biofuel Cells Industry

Updated Category News Views 119

Introduction to Paper-Based Biofuel Cells The paper-based biofuel cell (PBFC) market is on the verge of a significant transformation, expected to grow from a valuation of approximately US$ 385.29 million to over US$ 690.23 million by 2033. This remarkable growth reflects an annual growth rate of 7.56% as industries pivot increasingly towards sustainable energy solutions....

Continue Reading
AT&T and Ericsson Fly High with Drone Detection Demo

Updated Category News Views 72

Breaking Down the Drone Detection Demonstration The latest outing from AT&T and Ericsson isn't just tech eye candy—it's a dose of reality wrapped in tomorrow's promise. The goliath telecom duo pulled off a drone detection demo over 5G near AT&T Stadium in Arlington, Texas. What grabs headlines here isn't just the demonstration's success but how it smudges the line...

Continue Reading
Minerva University Launches Innovative Leadership Program in Tokyo

Updated Category News Views 196

Minerva University Launches Innovative Leadership Program The renowned Minerva University has introduced an exciting initiative designed to prepare global executives to effectively navigate today's complex world. The World Wise Executive Leadership Development Program, supported by the Nippon Foundation, focuses on developing leadership skills necessary for thriving in...

Continue Reading
Alpha Omega Partners with USDA to Boost Crop Insurance Support

Updated Category News Views 221

Alpha Omega Secures Contract with USDA to Enhance Crop Insurance Alpha Omega, a leader in digital modernization and cybersecurity, has landed a significant contract with the U.S. Department of Agriculture (USDA). This collaboration is set to enhance the USDA's crop insurance programs, which are essential for safeguarding farmers and ranchers against the growing challenges...

Continue Reading